BridgeBio Pharma Operating Margin 2018-2024 | BBIO
Current and historical operating margin for BridgeBio Pharma (BBIO) over the last 10 years. The current operating profit margin for BridgeBio Pharma as of September 30, 2024 is -243.68%.
| BridgeBio Pharma Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2024-09-30 |
$0.22B |
$-0.55B |
-250.00% |
| 2024-06-30 |
$0.22B |
$-0.51B |
-233.33% |
| 2024-03-31 |
$0.22B |
$-0.48B |
-219.63% |
| 2023-12-31 |
$0.01B |
$-0.61B |
-6070.00% |
| 2023-09-30 |
$0.01B |
$-0.56B |
-5590.00% |
| 2023-06-30 |
$0.01B |
$-0.53B |
-8833.33% |
| 2023-03-31 |
$0.08B |
$-0.46B |
-594.87% |
| 2022-12-31 |
$0.08B |
$-0.51B |
-656.41% |
| 2022-09-30 |
$0.09B |
$-0.55B |
-616.85% |
| 2022-06-30 |
$0.09B |
$-0.57B |
-625.27% |
| 2022-03-31 |
$0.07B |
$-0.58B |
-821.13% |
| 2021-12-31 |
$0.07B |
$-0.58B |
-836.23% |
| 2021-09-30 |
$0.06B |
$-0.54B |
-960.71% |
| 2021-06-30 |
$0.06B |
$-0.51B |
-820.97% |
| 2020-09-30 |
$0.02B |
$-0.43B |
-1936.36% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
